First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers

E.S. Koltun, J. Cregg, M.A. Rice, D.M. Whalen, R. Freilich, J. Jiang,  R. Hansen, A. Bermingham, J.E. Knox, J. Dinglasan, K.J. Seamon, C, Blaj, S.S. Chang, Y.Liu, J. Huang, K-J. Chou, L. McDowell, B.J. Lee, D. Wildes, Z.P. Wang, M. Singh, A.L. Gill, J.A.M. Smith